Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1190)	6/17/2000 4:56:00 PM
From: Oak Tree	Read Replies (1) \| Respond to of 52153

75 biotecks are a lot. I have some NABI now, did ok so far and might buy some more. Which of the 75 are your current favorites.

To: Biomaven who wrote (1190)	6/20/2000 11:05:00 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Some more thoughts on the Russell reconstitution. The annual reconstitution of Russell's 21 U.S. equity indexes captures the 3,000 largest U.S. stocks as of May 31, ranking them by market capitalization to create the Russell 3000(R) Index. The largest 1,000 companies in the ranking comprise the Russell 1000(R) Index while the remaining 2,000 companies comprise the small-cap Russell 2000(R) Index. After the preliminary list of additions and deletions for the Russell 3000 are posted, the rebalancing process continues through the month of June with updates set for June 16 and 23. The final, official list of companies in Russell's indexes will be made available July 10 after capitalization rankings are adjusted for mergers and other corporate changes. More than $175 billion is invested in funds using Russell's U.S. indexes as a model. About $85 billion uses the Russell 3000 (including the Russell 3000 Growth(R) Index and Russell 3000 Value(R) Index), about $68 billion uses the Russell 1000 (including the Russell 1000 Value(R) Index and Russell 1000 Growth(R) Index) and more than $16 billion uses the Russell 2000 (including the Russell 2000 Growth(R) Index and Russell 2000 Value(R) Index.) I've been trying to figure out the total net inflow into the lower tier-biotech from these additions. We have $16 billion indexed directly to the 2000. Next we have $85 billion indexed to the 3000, of which 92% must represent the larger 1000, leaving another $7 billion for the 2000. This gives a total of $23 billion indexed to the 2000, or an average of $11.5 million per company. That implies an inflow of about $750 million into the lower tier biotechs over the next month, which is a pretty significant hunk of change. Peter